<DOC>
	<DOCNO>NCT00075452</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine oxaliplatin , work different way stop tumor cell divide stop grow die . It yet know whether gemcitabine effective without oxaliplatin treat pancreatic adenocarcinoma . PURPOSE : This randomized phase III trial study gemcitabine oxaliplatin see well work compare gemcitabine alone treat patient locally advance metastatic unresectable pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Gemcitabine With Without Oxaliplatin Treating Patients With Locally Advanced Metastatic Unresectable Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient locally advance metastatic unresectable pancreatic adenocarcinoma treat gemcitabine without oxaliplatin . Secondary - Compare time response patient treat regimen . - Compare clinical benefit tolerance regimens patient . - Compare quality life patient treat regimen . - Compare progression-free survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , ECOG performance status ( 0 1 v 2 ) , extent disease ( locally advance vs metastatic ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute weekly week 1-7 9-11 absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine IV 100 minute day 1 oxaliplatin IV 2 hour day 2 . Courses repeat every 14 day 3 month absence disease progression unacceptable toxicity . After completion chemotherapy , patient locally advanced disease receive chemoradiotherapy . Quality life assess baseline every 2 month . PROJECTED ACCRUAL : A total 230 patient ( 115 per treatment arm ) accrue study within 24 month .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm pancreatic adenocarcinoma Locally advance metastatic disease Unresectable disease Measurable disease At least 2 cm classical scanner least 1 cm spiral scanner No adenocarcinoma bile ducts ampulla Vater No known brain metastasis PATIENT CHARACTERISTICS : Age 18 75 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 12 week Hematopoietic Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic Bilirubin less 1.5 time normal Alkaline phosphatase less 5 time normal Renal Creatinine less 1.5 time normal No uncontrolled persistent hypercalcemia Cardiovascular No serious cardiac failure Pulmonary No serious respiratory failure Other Pain must stabilize control initiation study treatment Not pregnant nursing Fertile patient must use effective contraception No untreatable malignant tumor No serious psychological , familial , social , geographical condition would preclude study participation No neuropathy would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy No concurrent corticosteroid except antiemetic therapy Radiotherapy No prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>